Identification of Antibodies against Human Papillomavirus Type 16 E6 and E7 Protein in Sera of Patients with Cervical Neoplasias

我们利用在大肠杆菌中表达的人乳头瘤病毒（HPV） 16e6和E7的10-融合蛋白，建立了一种灵敏、特异的ELISA方法。对97名妇女（30名浸润性宫颈癌患者、26名宫颈上皮内肿瘤III （CIN III）患者和38名健康妇女）的血清进行E6和E7蛋白抗体检测。30例宫颈癌血清中有8例（27%），26例CIN血清中有5例（19%），38例正常血清中无E6蛋白反应（截止点：吸光度(A)=0.59, x+3SD）。30例宫颈癌血清中有10例（33%），26例CINⅲ血清中有2例（8%），38例正常血清中无E7蛋白反应（截断点：A=0.40, x+3SD）。肿瘤患者中e7抗体阳性的平均吸光度高于CIN III患者，而E6抗体阳性的平均吸光度在两组间无差异。有趣的是，12种与E6或E7蛋白反应的癌症血清中有6种（50%）对这两种蛋白都有反应，而CIN III患者的血清中没有一种与这两种蛋白都有反应。HPV 16 E6和E7抗体与恶性转化相关的高患病率和高吸光度值表明，检测这些抗体可能是宫颈癌相关的HPV 16的有用诊断辅助。

We have developed a sensitive and specific ELISA method using the s10-fusion proteins of human papillomavirus (HPV) 16 E6 and E7, expressed in E.coli. Sera from 97 women(30 patients with invasive cervical cancers 26 patients with cervical intraepithelial neoplasea III (CIN III) and 38 healthy women) were tested for the presence of antibodies to E6 and E7 proteins. Eight (27%) of the 30 cervical cancer sera, five (19%) of the 26 CIN sera and none of the38 normal sera were reactive with E6 proteins(cut-off point : absorbance (A)=0.59, x+3SD). Ten (33%) of the 30 cervical cancer sera, two (8%) of the 26 CIN III sera and none of the 38 normal sera were reactive with E7 proteins (cut-off point : A=0.40, x+3SD). The mean absorbance for anti-E7 antibody in positive cases was higher in cancer patients than in CIN III patients, while that for E6 did not differ between these two groups. Interstingly, six (50%) of 12 cancer sera which reacted with either E6 or E7 proteins were reactive for both proteins, whereas none of the sera from the CIN III patients reacted with both proteins. The high prevalence rates and high absorbance values for HPV 16 E6 and E7 antibodies in association with malignant transformation suggest that detection of these antibodies may be a useful diagnostic aid for cervical cancer-associated HPV 16.